ESMO 新分析:靶向药 daraxonrasib 在晚期胰腺癌多人群强化生存获益
ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer
在欧洲肿瘤内科学会年会上展示的 RASolute 302 试验新增分析显示,口服靶向药 daraxonrasib 在不同 RAS 突变及未明确 RAS 突变的人群中仍优于标准化疗。
原文对RASolute 302 试验做了分子分层的补充分析,结果在多种 RAS 突变状态与化疗对照组中均一致,有助于判断该靶向药对晚期胰腺癌患者的适用范围。
A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation.
The findings, presented at the European Society for Medical Oncology (ESMO) Congress by Dr. Zev Wainberg, professor of medicine and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, build on earlier results from the RASolute 302 trial, which showed that patients with previously treated metastatic pancreatic cancer who received daraxonrasib lived a median of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy.
The latest analysis provides additional evidence that the treatment consistently provided a benefit across a broad range of patients with advanced pancreatic cancer, regardless of their tumor's RAS mutation status or previous treatment history.
Why this matters
Pancreatic cancer remains one of the most difficult cancers to treat, particularly when the disease has spread to other parts of the body and progressed after initial treatment.
More than 90% of pancreatic cancers have mutations in RAS genes, which help control cell growth. When mutated, these genes can continuously send signals that drive cancer growth. In this study, researchers collected detailed molecular information on all RAS mutation subsets, providing one of the largest detailed molecular analyses in metastatic pancreatic cancer.
Daraxonrasib is an oral targeted therapy designed to block multiple forms of the active RAS protein, including both mutated and nonmutated forms. Unlike treatments that target a single genetic mutation, daraxonrasib may be effective across a wider range of pancreatic tumors.
The drug, marketed as RASONQUE, received FDA approval in August 2026 for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
What the study did
Researchers conducted additional analyses of the phase 3 RASolute 302 trial, which included approximately 500 patients with metastatic pancreatic cancer who had previously received treatment.
Patients were randomly assigned to receive either daraxonrasib, taken as a daily pill, or one of several standard chemotherapy regimens.
The new analysis examined whether the survival benefit differed based on the type of RAS mutation found in a patient's tumor, the chemotherapy regimen selected for comparison and the setting in which patients had received earlier treatment.
What they found
The researchers found that survival outcomes consistently favored daraxonrasib over chemotherapy across the RAS mutation groups examined, including patients whose tumors did not have an identified RAS mutation.
The survival benefit was also consistent across different chemotherapy treatment groups, suggesting that the drug's effectiveness was not limited to comparisons with one particular chemotherapy regimen.
What this means for patients
"This update represents the largest analysis of any RAS inhibitor across all RAS mutation subgroups. In this analysis, we demonstrate that depending on the individual mutation, daraxonrasib may have a different response," said Wainberg. "These data have important implications for planning the next wave of RAS-targeted therapies with the ultimate goal of completely replacing chemotherapy."
While the additional analyses support the earlier findings, some patient subgroups were small, and further follow-up will help researchers better understand the long-term benefits across different patient populations.
Key medical concepts
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer (2026, October 23) retrieved 23 October 2026 from https://medicalxpress.com/news/2026-10-esmo-analysis-survival-benefits-therapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com